Multicellular living organisms and unmodified parts thereof and – Nonhuman animal – The nonhuman animal is a model for human disease
Reexamination Certificate
2004-05-24
2008-12-02
Bertoglio, Valarie (Department: 1632)
Multicellular living organisms and unmodified parts thereof and
Nonhuman animal
The nonhuman animal is a model for human disease
C800S018000, C435S354000
Reexamination Certificate
active
07459601
ABSTRACT:
In methods for screening treatments for, and treatment of, neurodegenerative diseases, aggregation in neurons of NACP/α-synuclein is measured and expression of a non-amyloidogenic protein is stimulated in order to reduce the level aggregration. For purposes of screening agents for treatment of neurodegenerative disease, oxidative stress in the neuronal cells is stimulated by introducing a mixture of metal-ions and hydrogen peroxide. Examples of appropriate metals include iron, aluminum, and copper. After introduction of the agent under evaluation for stimulation of expression of non-amyloidogenic protein, the effectiveness is measured by testing for a decrease in the level of aggregation of NACP/α-synuclein. In an exemplary embodiment, the non-amyloidogenic protein is β-synuclein. The aggregation of NACP/α-synuclein is dependent upon the concentration of metal ions in the neuronal cells. In addition, the presence of chelating agents appears to modulate the build-up of NACP/α-synuclein aggregates which are responsible for synaptic and neuronal dysfunction.
REFERENCES:
patent: 6184351 (2001-02-01), Biere et al.
patent: 6504080 (2003-01-01), Van Der Putten
patent: 6780971 (2004-08-01), Wolozin et al.
patent: 0908727 (1999-04-01), None
Sigmund, 2000, Artheroscler. Thromb. Vasc. Biol., vol. 20, pp. 1425-1429.
Houdebine, 1994, J. Biotech. vol. 34, pp. 269-287.
Mullins, 1993, Hypertension, vol. 22, pp. 630-633.
Wall, RJ, 1997,Transgenic Animal Technology, Journal of Andrology, 18:236-239.
Taurog, 1988, HLA-B27 in inbred and non-inbred transgenic mice, Jour. Immunol. vol. 141, pp. 4020-4023.
Mullins, 1989, Expression of the DBA/2J Ren-2 gene in the adrenal gland of transgenic mice, EMBO J. vol. 8, pp. 4065-4072.
Mullins, 1996, J. Clin. Invest., vol. 98, pp. S37-S40.
Mullins, 1990, Nature, Fulminant hypertension in transgenic rats harbouring the mose Ren-2 gene, vol. 344, pp. 541-544.
Hammer, 1990, Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human beta-2m : An animal model of HLA-B27-associated human disorders, Cell, vol. 63, pp. 1099-1112.
Rockenstein, E.M. et al., 1995, Jour Biol Chem, 2701:28257-28267.
Alberts, B et al, in Molecular Biology of the Cell, Garland Publishing, Inc. New York and London, 3rd Edition at p. 466.
Goldberg, MS et al., Nov. 1998, Society for Neuroscience Abstracts 24:966, Abstract 378.1.
Sommer, B et al., 2000, Experimental Gerontology, vol. 35, pp. 1389-1403.
Alberts, B et al, in Molecular Blology of the Cell, Garland Publishing, Inc. New York and London, 3rdedition, 1994 at p. 466.
Bauminger et al., Biochemistry (1999) 38:7791-7802.
Jenner et al., Annals of Neurology (1998) 44(Supp.1):S72-S84.
Korge et al., Archives of Biochemistry and Biophysics (1993) 304:420-428.
Lutz et al., Mut. Res. (1990) 238 (abstract only).
Spillantini, M.G. et al. α-Synuclein in Lewy bodies. Nature. 388:839-40. 1997.
Guptasarma et al., Biochemistry (1992) 31:4296-4303.
Jensen et al., Biochem J. (1997) 323:539-546.
Restriction Requirement from U.S. Appl. No. 09/806,842, mailed on Jul. 29, 2003.
Response to Election Requirement from U.S. Appl. No. 09/806,842, filed on Aug. 28, 2003.
Non-Final Rejection from U.S. Appl. No. 09/806,842, mailed on Nov. 4, 2003.
Amendment from U.S. Appl. No. 09/806,842, filed on Feb. 2, 2004.
Final Rejection from U.S. Appl. No. 09/806,842, mailed on May 5, 2004.
Restriction Requirement from U.S. Appl. No. 09/806,842, mailed on Oct. 29, 2004.
Amendment in Response to Non-Final Office Action from U.S. Appl. No. 09/806,842, filed on Nov. 18, 2004.
Final Rejection from U.S. Appl. No. 09/806,842, mailed on Mar. 30, 2005.
Amendment After Final Action (37 CFR Section 1.116) from U.S. Appl. No. 09/806,842, filed on May 31, 2005.
Non-Final Rejection from U.S. Appl. No. 09/806,842, mailed on Nov. 15, 2005.
Amendment Under 37 CFR § 1.111 from U.S. Appl. No. 09/806,842, filed on Feb. 15, 2006.
Final Rejection from U.S. Appl. No. 09/806,842, mailed on May 16, 2006.
Amendment After Final Action (37 CFR Section 1.116) from U.S. Appl. No. 09/806,842, filed on Jul. 11, 2006.
Notice of Allowance from U.S. Appl. No. 09/806,842, mailed on Aug. 24, 2006.
Notice of Allowance from U.S. Appl. No. 09/806,842, mailed on Jan. 29, 2007.
Harris et al., Experimental Neurology (1995) 131(2):193-202.
Hashimoto et al., The Journal of Biological Chemistry (1999) 274(41):28849-28852.
Narhi et al., The Journal of Biological Chemistry (1999) 274(14):9843-9846.
Perez and Hastings, Journal of Neurochemistry (2004) 89(6):1318.
Hashimoto et al., Brain Research (1998) 799(2):301-306.
Hashimoto et al., Neuroport (1999) 10(4):717-721.
Office Action for European Application No. 99950172.9, date mailed on Mar. 5, 2007, 4 pages.
Mizuno et al., Annals of Neurology (1998) 44(3 Suppl. 1):S99-S109.
Hashimoto Makoto
Masliah Eliezer
Mucke Lennart
Rockenstein Edward
Bertoglio Valarie
Morrison & Foerster / LLP
The Regents of the University of California
LandOfFree
Human α synuclein expressing transgenic mice does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Human α synuclein expressing transgenic mice, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human α synuclein expressing transgenic mice will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4036262